___

• Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary populationbased study. Arch Intern Med 1998;158(6):585 – 93. a 25-year
• Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293(6):715 – 22.
• Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100(10):3484 – 88. bleeding
• Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference Thrombolytic Therapy. Chest 2004;126(Suppl 3):338S –400S. and
• Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002;87(4):575 – 79.
• Mohren M, Markmann I, Jentsch-Ullrich K, Koenigsmann M, Lutze G, Franke A. Increased risk of thromboembolism in patients with malignant lymphoma: a single-centre analysis. Br J Cancer 2005;92(8):1349 – 51.
• Ottinger H, Belka C, Kozole G, Engelhard M, Meusers P, Paar D, et al. Deep venous thrombosis and pulmonary artery embolism in high-grade incidence, causes and prognostic relevance. Eur J Haematol 1995;54(3):186 – 94.
• Komrokji RS, Uppal NP, Khorana AA, Lyman GH, Kaplan KL, Fisher RI, Francis CW. Venous thromboembolism in patients with diffuse Lymphoma. 2006 Jun;47(6):1029–33 lymphoma. Leuk 9. Jaffe ,E.S.,Haris,N.L.,Stein,H.&Vardiman,J.W.Worl d Health Organization Classification of Tumours.Pathologyand Genetics of Tumours of Haemotopoetic and Lymphoid Tissues.2001. IARC Pres,Lyon
• Nordström M, Lindblad B, Anderson H, Bergqvist D, Kjellström T. Deep venous thrombosis epidemiological study. BMJ. 1994;308(6933): 891-94. malignancy: an
• Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78(5):285–91.
• Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost. 1999;25(2):173–82.
• Falanga A. Mechanisms of hypercoagulation in malignancy Haemostasis. 1998;28(suppl S3):50–60. chemotherapy.
• Meininger V, James JM, Rio B, Zittoun R. Dural venoussinus thrombosis in blood diseases. Rev Neurol 1985;141(3):228–33
• Gosk-Bierska I, Wysokinski W, Brown RD, Karnicki K, Grill D, Wiste H, et al. Cerebral venous thrombosis: incidence of venous thrombosis recurrence and survival. Neurology 2006;67(5):814–19
• Thodiyil PA, Walsh DC, Kakkar AK. Thromboprophylaxis in the cancer patient.Acta Haematol. 2001; 106(1-2):73-80.
• Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular- weight heparin versus a coumarin for the prevention thromboembolism in patients with cancer. N Engl J Med 2003;349(2):146 –53. venous
• Amezyane T, Lecoules S, Bordier L, Blade JS, Desramé J, Bechade D, et al.. Humoral hypercalcemia revealing a malignant non hodgkin lymphoma. Ann Endocrinol (Paris). 2008 Feb;69(1):58-62
• Mundy GR: Pathophysiology of cancer- associated hyper calcemia, Semin Oncol 1990, (suppl 5) 17: 10-5.
• Broadus AE, Mangin M, Ikeda K, Insogna KL, Weir EC, Burtis WJ, Stewart. AF. Humoral hypercalcemia of cancer: Identification of a novel parathyroid hormone-like peptide. N Engl J Med 1988;319(9):556-63.
• Burtis WJ, WU TE, Insogna KE, Stewart AF. Humoral hypercalcemia of malignancy. Ann Intern Med 1988;108(3):454-57.
• Virgolini L, Gallizia C. Hypercalcemia and neoplasms: recent advances in pathogenesis. Recenti Prog Med. 1990;81(10):635-41
• Lumachi F, Brunello A, Roma A, Basso U. Medical treatment of malignancy-associated hypercalcemia. 2008;15(4):415-21. Med Chem. Sorumlu Yazar Dr. Yakup Türkel Ondokuz Mayıs Üniversitesi Tıp Fakültesi Nöroloji Anabilim Dalı 55139 SAMSUN Tel: 5058617372 E-Mail: yturkel2002@mynet.com.tr